Marshall Wace’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-16,686
| Closed | -$360K | – | 3185 |
|
|
2025
Q4 | $360K | Sell |
16,686
-509,019
| -97% | -$9.88M | ﹤0.01% | 2383 |
|
|
2025
Q3 | $8.03M | Buy |
+525,705
| New | +$6.84M | 0.01% | 1002 |
|
|
2025
Q2 | – | Sell |
-314,343
| Closed | -$2.46M | – | 2696 |
|
|
2025
Q1 | $2.46M | Buy |
+314,343
| New | +$2.63M | ﹤0.01% | 1383 |
|
|
2024
Q4 | – | Sell |
-195,892
| Closed | -$2.57M | – | 2574 |
|
|
2024
Q3 | $2.57M | Buy |
+195,892
| New | +$2.98M | ﹤0.01% | 1272 |
|
|
2024
Q2 | – | Sell |
-383,641
| Closed | -$6.48M | – | 2536 |
|
|
2024
Q1 | $6.48M | Buy |
383,641
+229,056
| +148% | +$3.41M | 0.01% | 890 |
|
|
2023
Q4 | $2.18M | Sell |
154,585
-306,218
| -66% | -$3.6M | ﹤0.01% | 1183 |
|
|
2023
Q3 | $4.75M | Sell |
460,803
-148,223
| -24% | -$1.99M | 0.01% | 884 |
|
|
2023
Q2 | $10M | Buy |
609,026
+301,151
| +98% | +$3.91M | 0.02% | 726 |
|
|
2023
Q1 | $2.82M | Buy |
+307,875
| New | +$2.53M | 0.01% | 1270 |
|
|
2022
Q3 | – | Sell |
-11,081
| Closed | -$27K | – | 3323 |
|
|
2022
Q2 | $27K | Sell |
11,081
-82,046
| -88% | -$337K | ﹤0.01% | 3351 |
|
|
2022
Q1 | $636K | Buy |
+93,127
| New | +$640K | ﹤0.01% | 2662 |
|
|
2020
Q4 | – | Sell |
-131,270
| Closed | -$661K | – | 1868 |
|
|
2020
Q3 | $661K | Buy |
+131,270
| New | +$955K | ﹤0.01% | 1159 |
|
|
2015
Q1 | – | Sell |
-275,983
| Closed | -$4.73M | – | 793 |
|
|
2014
Q4 | $4.73M | Buy |
275,983
+161,656
| +141% | +$2.31M | 0.06% | 319 |
|
|
2014
Q3 | $1.64M | Buy |
+114,327
| New | +$1.64M | 0.02% | 478 |
|
Other funds holding AVDL
Marshall Wace's AVDL Position: Q1 2026 in Review
Marshall Wace sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 16,686 shares — an estimated $360K sold.
Marshall Wace first reported a position in AVDL in Q3 2014 and held it in 14 quarters. The position peaked at $10M in Q2 2023. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Marshall Wace reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Marshall Wace sold 16,686 Avadel Pharmaceuticals shares in Q1 2026, an estimated $360K.
- Marshall Wace first reported a position in Avadel Pharmaceuticals in Q3 2014 and held it in 14 quarters.
- Marshall Wace's Avadel Pharmaceuticals position peaked at $10M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.